Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.

Miller JS, Warren EH, van den Brink MR, Ritz J, Shlomchik WD, Murphy WJ, Barrett AJ, Kolb HJ, Giralt S, Bishop MR, Blazar BR, Falkenburg JH.

Biol Blood Marrow Transplant. 2010 May;16(5):565-86. doi: 10.1016/j.bbmt.2010.02.005. Epub 2010 Feb 10.

2.

Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.

Chen G, Wu D, Wang Y, Cen J, Feng Y, Sun A, Tang X, Chang H, Zhu Z.

Eur J Haematol. 2008 Sep;81(3):226-35. doi: 10.1111/j.1600-0609.2008.01108.x. Epub 2008 Jun 28.

PMID:
18573173
4.

NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.

Alyea EP, DeAngelo DJ, Moldrem J, Pagel JM, Przepiorka D, Sadelin M, Young JW, Giralt S, Bishop M, Riddell S.

Biol Blood Marrow Transplant. 2010 Aug;16(8):1037-69. doi: 10.1016/j.bbmt.2010.05.005. Epub 2010 May 24. Review.

5.

Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.

Spierings E, Kim YH, Hendriks M, Borst E, Sergeant R, Canossi A, Oudshoorn M, Loiseau P, Dolstra H, Markiewicz M, Leffell MS, Pereira N, Kircher B, Turpeinen H, Eliaou JF, Gervais T, Laurin D, Enczmann J, Martinetti M, Thomson J, Oguz F, Santarone S, Partanen J, Siekiera U, Alessandrino EP, Kalayoglu S, Brand R, Goulmy E.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1244-53. doi: 10.1016/j.bbmt.2013.06.001. Epub 2013 Jun 10.

6.

NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science.

Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH.

Biol Blood Marrow Transplant. 2010 Jun;16(6):709-28. doi: 10.1016/j.bbmt.2010.03.002. Epub 2010 Mar 12.

7.

Non-myeloablative transplants for malignant disease.

Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH.

Hematology Am Soc Hematol Educ Program. 2001:375-91. Review.

8.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.

de Lima M, Porter DL, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Schmid C.

Biol Blood Marrow Transplant. 2014 Jan;20(1):4-13. doi: 10.1016/j.bbmt.2013.08.012. Epub 2013 Sep 7.

9.

Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.

Kumar AJ, Hexner EO, Frey NV, Luger SM, Loren AW, Reshef R, Boyer J, Smith J, Stadtmauer EA, Levine BL, June CH, Porter DL, Goldstein SC.

Biol Blood Marrow Transplant. 2013 Jul;19(7):1094-101. doi: 10.1016/j.bbmt.2013.04.021. Epub 2013 Apr 28.

10.

Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation.

Ho VT, Kim HT, Kao G, Cutler C, Levine J, Rosenblatt J, Joyce R, Antin JH, Soiffer RJ, Ritz J, Avigan D, Alyea EP 3rd.

Am J Hematol. 2014 Dec;89(12):1092-6. doi: 10.1002/ajh.23825. Epub 2014 Aug 27.

11.

Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival.

Rubio MT, Moreira-Teixeira L, Bachy E, Bouillié M, Milpied P, Coman T, Suarez F, Marcais A, Sibon D, Buzyn A, Caillat-Zucman S, Cavazzana-Calvo M, Varet B, Dy M, Hermine O, Leite-de-Moraes M.

Blood. 2012 Sep 6;120(10):2144-54. doi: 10.1182/blood-2012-01-404673. Epub 2012 Jun 22.

12.

[Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].

Chang YJ, Huang XJ.

Beijing Da Xue Xue Bao. 2009 Apr 18;41(2):208-11. Chinese.

14.

The allogeneic graft-versus-cancer effect.

Ringdén O, Karlsson H, Olsson R, Omazic B, Uhlin M.

Br J Haematol. 2009 Dec;147(5):614-33. doi: 10.1111/j.1365-2141.2009.07886.x. Epub 2009 Sep 4. Review.

PMID:
19735262
15.

Enrichment of IL-12-producing plasmacytoid dendritic cells in donor bone marrow grafts enhances graft-versus-leukemia activity in allogeneic hematopoietic stem cell transplantation.

Darlak KA, Wang Y, Li JM, Harris WA, Owens LM, Waller EK.

Biol Blood Marrow Transplant. 2013 Sep;19(9):1331-9. doi: 10.1016/j.bbmt.2013.06.016. Epub 2013 Jun 27.

16.

Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.

Falkenburg JH, Marijt WA, Heemskerk MH, Willemze R.

Curr Opin Hematol. 2002 Nov;9(6):497-502. Review.

PMID:
12394171
17.

Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.

Talmadge JE.

Int Immunopharmacol. 2003 Aug;3(8):1121-43. Review.

PMID:
12860168
18.

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.

Pavletic SZ, Kumar S, Mohty M, de Lima M, Foran JM, Pasquini M, Zhang MJ, Giralt S, Bishop MR, Weisdorf D.

Biol Blood Marrow Transplant. 2010 Jul;16(7):871-90. doi: 10.1016/j.bbmt.2010.04.004. Epub 2010 Apr 24. Review.

19.

Prevention of GVHD without losing GVL effect: windows of opportunity.

Zhang P, Chen BJ, Chao NJ.

Immunol Res. 2011 Apr;49(1-3):49-55. doi: 10.1007/s12026-010-8193-7. Review.

PMID:
21136200
20.

The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.

Tsirigotis P, Shimoni A, Nagler A.

Ann Med. 2014 Sep;46(6):384-96. doi: 10.3109/07853890.2014.918463. Epub 2014 Jun 3. Review.

PMID:
24888385
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk